Login to Your Account

Other GLP-1s Coming Up Fast

Amylin, Alkermes Hit Hard on Surprise Bydureon Rejection

By Jennifer Boggs

Thursday, October 21, 2010
About the only good news for Amylin Pharmaceuticals Inc. Wednesday was that investors were unlikely to pay mind to the fact that third-quarter sales of diabetes drug Byetta (exenatide) missed analyst expectations, as shares of the San Diego-based biotech were hammered on a complete response letter and the prospect of a two-year delay for its once-weekly version of the GLP-1 agonist. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription